Sorrento announced COVIDTRAP(STI-4398) demonstrated in preclinical studies its ability to completely inhibit SARS-CoV-2 viral infection In vitro
On Jun. 5, 2020, Sorrento announced it had completed a preclinical batch of the STI-4398 (COVIDTRAP) protein and…